Synthesis and Pharmacology of the enantiomers of the potential atypical antipsychotic agents 5-OMe-BPAT and 5-OMe-(2,6-di-OMe)-BPAT

Bioorg Med Chem. 1999 Jul;7(7):1263-71. doi: 10.1016/s0968-0896(99)00073-5.

Abstract

The optically pure enantiomers of the potential atypical antipsychotic agents 5-methoxy-2-[N-(2-benzamidoethyl)-N-n-propylamino]tetralin (5-OMe-BPAT, 5) and 5-methoxy-2-{N-[2-(2,6-dimethoxy)benzamidoethyl]-N-n-propylamino}t etralin [5-OMe-(2,6-di-OMe)-BPAT, 6] were synthesized and evaluated for their in vitro binding affinities at alpha1-, alpha2-, and beta-adrenergic, muscarinic, dopamine D1, D2A, and D3, and serotonin 5-HT1A and 5-HT2 receptors. In addition, their intrinsic efficacies at serotonin 5-HT1A receptors were established in vitro. (S)- and (R)-5 had high affinities for dopamine D2A, D3, and serotonin 5-HT1A receptors, moderate affinities for alpha1-adrenergic and serotonin 5-HT2 receptors, and no affinity (Ki > 1000 nM) for the other receptor subtypes. (S)- and (R)-6 had lower affinities for the dopamine D2A and the serotonin 5-HT1A receptor, compared to (S)- and (R)-5, and hence showed some selectivity for the dopamine D3 receptor. The interactions with the receptors were stereospecific, since the serotonin 5-HT1A receptor preferred the (S)-enantiomers, while the dopamine D2A and D3 receptors preferred the (R)-enantiomers of 5 and 6. The intrinsic efficacies at the serotonin 5-HT1A receptor were established by measuring their ability to inhibit VIP-induced cAMP production in GH4ZD10 cells expressing serotonin 5-HT1A receptors. Both enantiomers of 5 behaved as full serotonin 5-HT1A receptor agonists in this assay, while both enantiomers of 6 behaved as weak partial agonists. The potential antipsychotic properties of (S)- and (R)-5 were evaluated by establishing their ability to inhibit d-amphetamine-induced locomotor activity in rats, while their propensity to induce extrapyramidal side-effects (EPS) in man was evaluated by determining their ability to induce catalepsy in rats. Whereas (R)-5 was capable of blocking d-amphetamine-induced locomotor activity, indicative of dopamine D2 receptor antagonism, (S)-5 even enhanced the effect of d-amphetamine, suggesting that this compound has dopamine D2 receptor-stimulating properties. Since both enantiomers also were devoid of cataleptogenic activity, they are interesting candidates for further exploring the dopamine D2/serotonin 5-HT1A hypothesis of atypical antipsychotic drug action.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amphetamine / pharmacology
  • Animals
  • Antipsychotic Agents / chemical synthesis
  • Antipsychotic Agents / metabolism*
  • Antipsychotic Agents / pharmacology*
  • Benzamides / chemical synthesis*
  • Benzamides / metabolism*
  • Benzamides / pharmacology*
  • Catalepsy / chemically induced
  • Cells, Cultured
  • Cyclic AMP / metabolism
  • Dopamine Agents / chemical synthesis
  • Dopamine Agents / metabolism
  • Dopamine Agents / pharmacology
  • Humans
  • Inhibitory Concentration 50
  • Isomerism
  • Male
  • Motor Activity / drug effects
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Adrenergic, alpha-1 / metabolism
  • Receptors, Adrenergic, alpha-2 / metabolism
  • Receptors, Adrenergic, beta / metabolism
  • Receptors, Dopamine D1 / metabolism
  • Receptors, Dopamine D2 / metabolism
  • Receptors, Dopamine D3
  • Receptors, Serotonin / metabolism
  • Receptors, Serotonin, 5-HT1
  • Remoxipride / metabolism
  • Serotonin Agents / chemical synthesis
  • Serotonin Agents / metabolism
  • Serotonin Agents / pharmacology
  • Structure-Activity Relationship
  • Tetrahydronaphthalenes / chemical synthesis*
  • Tetrahydronaphthalenes / metabolism*
  • Tetrahydronaphthalenes / pharmacology*
  • Vasoactive Intestinal Peptide / pharmacology

Substances

  • 5-methoxy-2-(N-(2-(2,6-dimethoxy)benzamidoethyl)-N-n-propylamino)tetralin
  • 5-methoxy-2-(N-(2-benzamidoethyl)-N-n-propylamino)tetralin
  • Antipsychotic Agents
  • Benzamides
  • DRD3 protein, human
  • Dopamine Agents
  • Drd3 protein, rat
  • Receptors, Adrenergic, alpha-1
  • Receptors, Adrenergic, alpha-2
  • Receptors, Adrenergic, beta
  • Receptors, Dopamine D1
  • Receptors, Dopamine D2
  • Receptors, Dopamine D3
  • Receptors, Serotonin
  • Receptors, Serotonin, 5-HT1
  • Serotonin Agents
  • Tetrahydronaphthalenes
  • Remoxipride
  • Vasoactive Intestinal Peptide
  • Amphetamine
  • Cyclic AMP